Affinity DataIC50: 2.20nMpH: 8.0 T: 2°CAssay Description:To assess the inhibitory activity of novel inhibitors, the PARP-1 enzyme assay was carried out in reaction mixture consisting of Escherichia coli str...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMpH: 8.0 T: 2°CAssay Description:To assess the inhibitory activity of novel inhibitors, the PARP-1 enzyme assay was carried out in reaction mixture consisting of Escherichia coli str...More data for this Ligand-Target Pair
Affinity DataIC50: 6.90nMpH: 8.0 T: 2°CAssay Description:To assess the inhibitory activity of novel inhibitors, the PARP-1 enzyme assay was carried out in reaction mixture consisting of Escherichia coli str...More data for this Ligand-Target Pair
Affinity DataIC50: 7.30nMpH: 8.0 T: 2°CAssay Description:To assess the inhibitory activity of novel inhibitors, the PARP-1 enzyme assay was carried out in reaction mixture consisting of Escherichia coli str...More data for this Ligand-Target Pair
Affinity DataIC50: 20nMpH: 8.0 T: 2°CAssay Description:To assess the inhibitory activity of novel inhibitors, the PARP-1 enzyme assay was carried out in reaction mixture consisting of Escherichia coli str...More data for this Ligand-Target Pair
Affinity DataIC50: 29.8nMpH: 8.0 T: 2°CAssay Description:To assess the inhibitory activity of novel inhibitors, the PARP-1 enzyme assay was carried out in reaction mixture consisting of Escherichia coli str...More data for this Ligand-Target Pair
Affinity DataIC50: 60nMpH: 8.0 T: 2°CAssay Description:To assess the inhibitory activity of novel inhibitors, the PARP-1 enzyme assay was carried out in reaction mixture consisting of Escherichia coli str...More data for this Ligand-Target Pair
Affinity DataIC50: 92.7nMpH: 8.0 T: 2°CAssay Description:To assess the inhibitory activity of novel inhibitors, the PARP-1 enzyme assay was carried out in reaction mixture consisting of Escherichia coli str...More data for this Ligand-Target Pair
Affinity DataIC50: 106nMpH: 8.0 T: 2°CAssay Description:To assess the inhibitory activity of novel inhibitors, the PARP-1 enzyme assay was carried out in reaction mixture consisting of Escherichia coli str...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform(Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: 110nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Affinity DataIC50: 110nMpH: 8.0 T: 2°CAssay Description:To assess the inhibitory activity of novel inhibitors, the PARP-1 enzyme assay was carried out in reaction mixture consisting of Escherichia coli str...More data for this Ligand-Target Pair
Affinity DataIC50: 149nMpH: 8.0 T: 2°CAssay Description:To assess the inhibitory activity of novel inhibitors, the PARP-1 enzyme assay was carried out in reaction mixture consisting of Escherichia coli str...More data for this Ligand-Target Pair
Affinity DataIC50: 160nMpH: 8.0 T: 2°CAssay Description:To assess the inhibitory activity of novel inhibitors, the PARP-1 enzyme assay was carried out in reaction mixture consisting of Escherichia coli str...More data for this Ligand-Target Pair
Affinity DataIC50: 428nMpH: 8.0 T: 2°CAssay Description:To assess the inhibitory activity of novel inhibitors, the PARP-1 enzyme assay was carried out in reaction mixture consisting of Escherichia coli str...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: 450nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [H1047R](Homo sapiens (Human))
Petra Pharma
US Patent
Petra Pharma
US Patent
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair